Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Aug;47(8):654-9.
doi: 10.1136/ard.47.8.654.

Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations

M Tishler  1 , D Caspi, T O Rosenbach, B Fishel, I Wigler, R Segal, E Gazit, M Yaron
Affiliations

Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations

M Tishler et al. Ann Rheum Dis. 1988 Aug.

Abstract

In a prospective open study 44 Israeli patients with rheumatoid arthritis were treated with weekly low dose methotrexate (MTX) for up to 36 months. Nine patients withdrew from the study: six because of side effects and three due to inefficacy. One patient died of septicaemia following septic arthritis. Significant improvement, graded by Ritchie articular index, grip strength, physician's global assessment, erythrocyte sedimentation rate (ESR), and platelet counts, was noticed in response to treatment. Seronegative patients had a better clinical response. Transient gastrointestinal symptoms were common and correlated with increases of serum aspartate transaminase (AST). HLA-DR1 and DR7 were significantly associated with increased serum AST concentrations.

PubMed Disclaimer

References

    1. N Engl J Med. 1985 Mar 28;312(13):818-22 - PubMed
    1. Am J Med. 1985 Sep;79(3):331-7 - PubMed
    1. Ann Rheum Dis. 1968 Jan;27(1):64-6 - PubMed
    1. Am J Med Sci. 1951 Feb;221(2):176-82 - PubMed
    1. Arthritis Rheum. 1981 Oct;24(10):1308-15 - PubMed